Philips’ CT Focus at RSNA 2011 on iDose4 and Ingenuity Suite
Scott Smith, director of project management, CT, Philips Healthcare, describes low-dose CT as nearly a given in the marketplace now. What’s more important is maintaining the speed and quality of the image while using iterative reconstruction to keep the dose low.
Patient and hospital concern over CT dose has created a “perfect storm” for new products in CT, according to Gene Saragness, Philips’ EVP and CEO. Philips iDose4 has had the “fastest uptake I’ve seen in any product.” The Ingenuity CT with iDose4 was originally introduced at last year’s RSNA.
The company will put focus on its latest iDose technology at RSNA 2011.
Scott Smith, director of project management, CT, Philips Healthcare, describes low-dose CT as nearly a given in the marketplace now. What’s more important is maintaining the speed and quality of the image while using iterative reconstruction to keep the dose low.
iDose4 , he says, keeps the natural appearance of the object, despite its use of iterative reconstruction technology (see chest image to left), and keeps up the speed needed to make CT useful in trauma settings.
“The majority of reconstruction images happen in under 60 seconds,” Scott says.
Philips also will present its Ingenuity CT products as a suite, a sort of continuum of increasing sophistication. Scott describes it as “investment protection,” since customers can upgrade in-room.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
